Q-omics provides the consensus-scored STMN3 profile across patient tissues and cancer cell-line models. STMN3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, STMN3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, STMN3 RNA expression shows 17,726 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where STMN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STMN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STMN3 survival associations across molecular data types. STMN3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STMN3 RNA expression–survival associations across cancer types. High STMN3 expression shows unfavorable associations in UCS, ACC and UVM, but favorable associations in PAAD, LGG and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for STMN3 RNA expression.
This table summarizes STMN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STMN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STMN3 shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, COAD, KIRP and LUAD. The KIRC box plot shows higher STMN3 RNA expression in tumor versus normal tissue (log2 FC = +2.038, t-test p < 0.001).
This table shows molecular features associated with STMN3 in patient tissues and cancer cell lines. In patient samples, STMN3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STMN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
